426P Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care

Abstract

was given by intravenous infusion on day 1, q3w. After 6 cycles of inducing therapy, patients would receive anlotinib (12mg, po, d1w14, q3w) until disease progression or intolerable adverse events. The primary endpoint was PFS; Secondary endpoints included ORR, DCR, DOR and safety.Results: At the data cut-off date of April, 2021, a total of 21 patients were enrolled, the median (range) age was 58 (48-66) years, 15 (71%) were males, ECOG PS 0/1 was 10 (48%)/11 (52%), 18 (86%) had more than one metastatic tumor. Among 17 efficacy-available patients, the ORR (CR/PR) was 53% (9/17) and the DCR (CR/PR/SD) was 88% (15/17) in best overall response assessment, of which the longest duration of treatment was 12.1 months and the response was still ongoing. The median PFS was not reached. The Grade 3/4 treatment related adverse events(TRAE, 10%) were hypertension (19%), hypertriglyceridemia (14%), neutropenia (14%), lipase elevated (10%). One grade 5 TRAE was pancytopenia that occurred at 2.7 mths. Conclusions:The update results suggested that anlotinib combined with XELOX as first line regimen followed by anlotinib monotherapy showed a promising clinical benefit and favorable safety profile for mCRC. And the results needed to be confirmed in trials continued subsequently.